Seeking Alpha


Send Message
View as an RSS Feed
View johnjppa's Comments BY TICKER:
Latest  |  Highest rated
  • These Headwinds Make Organovo A Short Candidate [View article]
    Mukticat I know that I have tried to explain the science behind this product to you in the past, thinking that maybe you just didn't get it. I've held this stock for some 2 years or more and will continue to do so for a much longer period. I started at 1.90 or so and have stay the course up to 12.00 or so and then back down. I'll admit that I didn't understand the "market" nor did I understand how easily stocks could be manipulated by any jo that could get on a computer and just spout a ton of nonsensical BS. I'm sure if you go back and read my post you'll see that I was really trying to give some insight into the fundamentals of how this technology may impact the way we develop various treatments. The statements I made at the time were not so spectacular as I was trying to downplay the "printing of organs" or printing an arm etc.. You were one of the guys that was saying that they were touting these wild claims. And like I said then the potentials for accurate modeling of real tissues and the impact on medicine was extremely exciting to us researchers but to the average person on the street, not so much. I knew then that it would be 2-3 years before the clinical utility would just start to be realized and the appreciation of the stock would be based on real science. The actual applications go way beyond 3 D modeling of hepatocytes. This was the venue that they probably agreed could get them in the door the quickest. If you remember I argued at that time that this form of 3-D modeling was vastly superior to scaffolding techniques that was used by others. Because at that time another one of your arguments was that there were "many" other companies that did the same thing that were way ahead of ONVO and I went into detail trying to explain these differences. I knew then that it would still be several years before "the market" was ready for the facts and I do believe that Mr Murphy as brought this company along in such a way that these early and initial applications were adequately tested and presented into a marketable product. I'm a neurobiologist not a financial manager nor do I have any real understanding of how a new technology is developed to fully exploit investors interest or "institutional acceptance". In any case now there is a product that they can sell or will legitimize the technology and hopefully the company will be able to move way beyond having to prove anything and can start to move into a vast array of exciting areas where bioprinting tissue will change the way we conduct our research. These liver essays were only the early first steps that I guess were needed & to bring a product to the market. I am sure that this stock will still demonstrate some volatility but the days of guys like you having any impact based on your limited (no) knowledge of science hopefully are well behind us and we can get on with the discovery and let the folks that make money on it do their thing.
    Dec 13, 2014. 11:15 AM | 6 Likes Like |Link to Comment
  • Organovo: Why This 3-D Bioprinting Company Sold Off In A Hurry [View article]
    The problem here is that the public in general has no interest in a technology unless they think that an organ tranplants is 5-10 years down the road. However, ONVO offers a technology that no other offers. This is fact. A technology that will give researchers a tool that will completely wipe out the very earliest stages of experimental models In vivo and start experimenting with In vitro tissue models is an absolute huge step in financing and this is why the Univ. of Missouri has been involved. This means very little the the avg. person but to reseachers the financial benefit is outstanding. The P/E values may show that the company is worthless in dollars or capital. However, the folks that say there science is just like all these other companies, and that is just false. The value in dollars that researcher will pay for this short-cut is significant. That's's a short cut. How much is that worth. I guess you'd have to spend years in a lab experiencing failure after failure to be able to realize it's potential. And that's what PhD candidates do all the time. But a real model that will indicate whether their idea, their thought process is possible is just like is like Mastercard says... it's priceless....
    Nov 21, 2013. 08:13 AM | 1 Like Like |Link to Comment
  • A Very Detailed Look At Organovo [View article]
    Mr. Pearson, Spot on! Right on! great article!
    I'm selling right now thanks for saving me a lot of money.
    These post all have this same characteristics. Family members or some of his 46 followeres on his blog.
    Nov 20, 2013. 11:49 AM | Likes Like |Link to Comment
  • A Very Detailed Look At Organovo [View article]
    Neovasculization is in no way problematic. I would say they have not had time to focus on those cascades but as you know if a segmental nerve root can reinnervate then certainly the very basic proliferative phase and vascular extention is a small problem that will soon be addressed. It may take time and collaboration but not more than a year. Now keep in mind I have absolutely no knowledge of this company other than the science. However they obviously needed at this time to focus on what they have to work with and getting data out there to prove their basic science. What you must realize is protein manufacturing, peptide assembly will allow for any growth factor needed. Insulin like growth hormone, growth hormone releasing factor etc... What I see is the timing & blending of these technologies, with the assembly of basic proteins and long chain peptides will aid and allow researchers to essentially side step the religous right & their retardive influrance of scientific discovery.
    Nov 19, 2013. 10:32 PM | 2 Likes Like |Link to Comment
  • A Very Detailed Look At Organovo [View article]
    u sold months ago at $5 and u are thanking Richard for that?
    Nov 19, 2013. 06:20 PM | 1 Like Like |Link to Comment
  • A Very Detailed Look At Organovo [View article]
    I think people (public) picked up on some potential indications such as organ transplants etc... This would be some years down the road. However, the applications for this moldality is still so far reaching in things that would not interest most people. However, to most researchers their are many potential applications. The seeding of granulation tissue, synovium, possible treatments of spinal syrnx etc... If this company and Univ. of Missouri and the other parties that are directly involved and have other interest are able to fully protect there techniques the value will be huge. huge.
    Nov 19, 2013. 05:44 PM | 1 Like Like |Link to Comment
  • A Very Detailed Look At Organovo [View article]

    Look up the page I have several post and that clearly describes why ONVO product is different. Did you read the post. It's as clear as a bell working with microtissues soultions or immuno imaging through antigen/antib mech. is not the same as layer technology. Dude before you continue, I am sure that Organovo will put out responses to these other technologies very soon and hopefully they are trained (better than myself) how to present difficult biotech concepts to the non technical investors. Look at the post.
    I fine for a debate but address my above post "johnjppa" there's 2 others ...and let me know where my reasoning is off.
    Nov 19, 2013. 05:25 PM | 1 Like Like |Link to Comment
  • A Very Detailed Look At Organovo [View article]
    Richard has none of the facts correct and niether do you. If your saying a particular company is all hype please discuss the details of their specific moldalities versus these other companies in which Richard is saying ONVO is just another of...
    Please give real details not just a bunch of cliche or some old story about other companies and what you guys call "pump n dump" .
    Where are Richards answers to some these excellent points that some other posters wrote about. Please be specific.
    Nov 19, 2013. 04:13 PM | 3 Likes Like |Link to Comment
  • A Very Detailed Look At Organovo [View article]
    Richard I have no idea about how these investments inthese start up companies are manipulated. However, it's clear you do not understand the technology.
    I'm a neurophysiologist that has been working at the clinical level for many years & I'm merely an expert in my little corner. I no longer have the higher cortical function to try and understand this level of theory much less it's utilization. I do know however that this is the most interesting and promising technology that have have witnessed(ever). This will help in that big next step.
    How this company will profit from this will depend on their experts & how they handle this good fortune. I hope those experts (CEO's) are 1/2 as good as there biologist and engineers.
    Nov 19, 2013. 02:18 PM | 3 Likes Like |Link to Comment
  • A Very Detailed Look At Organovo [View article]
    It's obvious that the author has no expertise in the various techniques from biochemical, cytologic or a physiologic perspective. First, liver enzymes assays and this technology is NOT the same nor does it use scaffolding technology. These other companies (named above) employ this technique. To say apples to apples does not even apply here. Yes scaffolding technology is 3D but that is the whole POINT. They're all the same!!! This is what Oganovo offers, it different and it's as nature has constructed it. And what we PhD's and other clinical providers see in this technology goes way beyond liver assays. How Richard got so side tracked on the fact that all this techonlogy does is liver assays is ridiculous. This way of cytologically layering tissue as it occurs in organism will be the new gold standard for all biochemical & histologic modeling & can easy be tranformed into any clincal applications where advance modeling will save millions and millions in hard research resources and the applications are so widespread. You can't even speculate on all the various applications because they will extend into many fields such as oncology, hematology, neural, orthopaedic and the list goes on and on. It won't just be a technology for pharmaceuticals companies. Who came up with that idea... that it will only be used for toxicologic assays and so forth?? The "liver assay" was just a step of demonstrating a single clinical application. And you can not even compare scaffolding technology to pure cellular organization as it occurs anatomicalyl and physiologically in the organ system. You could test wind speeds on a likeness of a house built out of cardboard and use it as your "standard model". Or take your predictions of how these materials will hold up in the wind from building an actual house out of real bricks and morter & constructed exactly as people will live in.
    Nov 19, 2013. 01:51 PM | 13 Likes Like |Link to Comment
  • Vivus president resigns [View news story]
    I write thousand of prescriptions each year and feel that Vivus has really good products. I don't know how they could make such a cluster out of getting these products out on the market.
    If you can't make money with an amphetamine and with a fast acting ED drug... than somethings wrong.
    Oct 2, 2013. 02:20 PM | 1 Like Like |Link to Comment
  • Buy Arena, Sell Vivus As Qsymia's European Approval In Doubt [View article]
    You folks are talking about medications you know nothing about. Right now as we speak this moment in every city in the US and in Europe Adipex (phentermine) is being prescribed 50 million scripts per year. Phentermine has been around since the 50's, it's well tolerated. Qsymia = phentermine (amphetamine) there's no hidden side effects that we don't know about. Phentermine is a schedule IV. There is no risk in prescribing schedule IV's. In a 100,00 pop city there would easily 2 dozen practices that prescribed it on a regualr bases TODAY AS I WRITE THIS. If you don't think amphetamine work for weight loss. They do the same thing (increase dopamine) as cocaine. Use some common sense. Who cares about Europe they don't use diet pills anyways go online and type in adipex and see how many european pharmacy are selling generic phentermine to us. Belviq is.... porzac, paxil, effexor, zoloft. Belviq will have black box warning for suicide risk. That will kill it.
    Oct 5, 2012. 03:57 PM | Likes Like |Link to Comment
  • Has Vivus Bottomed Out? [View article]
    You must have some knowledge of the products. First Qsymia is composed of the number one anorexiant of all time selling 1000000 to 1 units per every other weight loss medication "combined" what is that medication "AMPHETAMINE".
    However, Belviq is an ssri (anti depressent) which are now being prescribed in a very limited amounts (for weight loss). SSRI's like redux's the same class and yes we still write these meds for weight loss think "effexor" no it's not FDA approved but considered off label use. Doesn't matter 20% of all scripts written are off lable. So as far as we physicians are concerned Belviq ARNA is just another SSRI. There is absolutely nothing new about this drug. It has exactly 100% the same action as prozac, effexor etc..they're all the same.
    Qsymia however has an amphetamine in it, which is very potent and has been around for 75 years. Now they've added Topamax to it "Qsymia" which is a great anorexiant in and of itself.
    Don't forget fen-phen is still available,
    phen-termine is adipex imported and written in USA for over 50 million scripts per year. The 2nd part of phen fen is dex fen -fluramine or "redux" and no redux is not used but you can substitute redux with any other ssri prozac, effexor, celexa they're all the same thing as redux. therefore there are millions of folks that still take fen-phen
    Don't get your facts from CNN. Don't fool yourself if you think an ssri can compete with an amphetamine they've been around for decades and have great properties including euphoria, increased energy and appetite suppression.
    Oct 2, 2012. 11:15 PM | 1 Like Like |Link to Comment
  • Buy Arena, Sell Vivus As Qsymia's European Approval In Doubt [View article]
    Because qsymia is an amphetamine which is by and far without question the most potent and widely prescribed anorexiant in the world. So getting approved was the hard part. However, patient will request an amphetamine over a anti depressant (Belviq) 100 to 1.
    There are more purchase of amphetamine products over the internet (to China alone) than any other medication, other than viagra.
    VVUS is sitting on a giant. And there are no surprises phentermine has been studied for 50 years and topamax is well known for the last 15 years.
    Oct 2, 2012. 01:47 PM | Likes Like |Link to Comment
  • Buy Arena, Sell Vivus As Qsymia's European Approval In Doubt [View article]
    Your a pharmacist and truly think another ssri is going to have a chance against a sympathomimetic (amphetamine) and topamax combo, both being the most potent anorexiants ever. Another SSRI (Belviq) because thats essentially what it is...and has all of the side effects of the ssri class. And about 15% of the population will actually gain weight. Phentermine is already the most widely prescribed diet drug. Now it is legitimatized by the addition of topamax. If we wanted to prescribe Belviq we would just write for effexor.And effexor is paid for by all insurers. When it come down to mechanism of action Belviq is just one of many. Why have ampetamines been around because they make people feel good and reduce their appetite.
    Oct 2, 2012. 12:32 PM | Likes Like |Link to Comment